1 Title page

2 Linear age-course association between non-alcoholic fatty liver disease, components of

- 3 metabolic syndrome, and mortality
- 4
- 5 Xinyu Zhao^{a,b}, Shuohua Chen^c, Xiao mo Wang^a , Zhenyu Wang^a , Yuanyuan Sun^a , Chenlu Yang^a ,
- 6 Mengyi Zheng^d, Yanhong Wang^a, Wei Liao^a, Shouling Wu^{c,*}, Li Wang^{a,*}
- 7
- 8 ^a Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese
- 9 Academy of Medical Sciences; School of Basic Medicine Peking Union Medical College, Beijing,
- 10 China
- ^bDepartment of Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical
- 12 University; National Clinical Research Center for Digestive Diseases, Beijing, China
- 13 ^c Department of Cardiology, Kailuan General Hospital, Tangshan, China
- ^d Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China

15 *Corresponding author:

- 16 Li Wang
- 17 Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese
- 18 Academy of Medical Sciences; School of Basic Medicine Peking Union Medical College, 5 Dong
- 19 Dan San Tiao, Beijing 100005, China. E-mail address: liwang@ibms.pumc.edu.cn
- 20 Shouling Wu
- Department of Cardiology, Kailuan General Hospital, Tangshan 063000, China. E-mail address:
 drwusl@163.com
- 23
- 24 The total word count of the manuscript: 4195
- 25

1 Abstract

Background: The study aimed to explore the relationship between non-alcoholic fatty liver
disease (NAFLD) and mortality by age and metabolic syndrome (MetS) components.

Method: We enrolled 104,173 participants in the Kailuan cohort from June 2006 through October
2013. Cox regression models were used to evaluate the hazard ratio (HR) and 95% confidence
interval (CI). Population-attributable fractions (PAFs) of metabolic components were also
calculated.

8 Results: Compared with non-NAFLD, the excess risk of all-cause and cardiovascular disease 9 (CVD)-related mortality in NAFLD increased with the number of MetS components but decreased 10 with age. The highest all-cause and CVD-related death risks were observed in NAFLD aged 18-39 11 with 4-5 MetS (HR=2.81, 95% CI:1.55-5.08) and those aged 40-49 years with 3 MetS (HR=2.25, 12 95% CI:1.55-5.08), respectively. However, there was no significant extra risk of liver-related 13 death in NAFLD patients of any age. For PAF, 28.5% of all-cause and 43.4% of CVD-related 14 mortality among NAFLD patients was preventable by controlling MetS components < 2, with the 15 highest PAF in those aged 50-69 and 18-49, respectively. Elevated blood pressure (PAF of 24.7% 16 for all-cause; 38.6% for CVD-related), elevated fasting glucose (PAF of 13.4% all-cause; 9.2% 17 CVD-related), and elevated triglycerides (PAF of 3.9% all-cause; 14.0% CVD-related) were the 18 essential mortality contributors in NAFLD participants.

19 Conclusion: The excess risk of all-cause and CVD-related mortality in NAFLD patients decreases 20 with age. A substantial proportion of risks could be averted if NAFLD patients are controlled 21 under two MetS components, especially managing blood pressure, fasting glucose, and 22 triglycerides for the young.

Key words: Non-alcoholic fatty liver disease; metabolic syndrome; mortality; attributable
 population fraction; cohort.

Abbreviations: non-alcoholic fatty liver disease (NAFLD); metabolic syndrome (MetS);
cardiovascular disease (CVD); elevated blood pressure (BP); systolic blood pressure (SBP);
diastolic blood pressure (DBP); elevated fasting blood glucose (FBG); triglyceride (TG); highdensity lipoprotein (HDL).

29

30

31

1 1. Introduction

2 Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide,

3 with a global prevalence of $30\%^1$. NAFLD may increase the risk of cardiovascular disease,

4 chronic kidney disease, and some specific cancers 2,3 . However, its impact on mortality is still

5 controversial due to the difference in the study population's characteristics and the diagnosis

6 method of NAFLD⁴⁻⁸. Most NAFLD-related mortality studies were based on western people or

7 limited by highly selected patient populations^{4,5,9,10}.

8 The participants with NAFLD are often accompanied by components of metabolic syndrome 9 (MetS). Studies have shown that the risk of all-cause mortality gradually increased with the number of components of MetS¹¹. Also, the early onset of the individual component of MetS, such 10 as obesity, diabetes, and hypertension, has been reported to have a higher risk of death than those 11 12 with late onset ¹²⁻¹⁴. Furthermore, our cohort study in a Northern Chinese population has shown a modified effect of age on the association between NAFLD and mortality¹⁵. All the above 13 14 information suggests that age may modify the effect of NAFLD on all-cause mortality. 15 Additionally, it is unclear what extent of deaths can be reduced by controlling MetS components 16 of NAFLD patients to normal levels.

Using the Kailuan cohort in China, we aimed to: (1) evaluate the association between the excess
risk of mortality among patients with NAFLD versus non-NAFLD participants by the number of
MetS components; (2) quantify the proportions of deaths in the NAFLD and non-NAFLD that can
be reduced by controlling different MetS components to normal levels.

21 2. Methods

22 2.1 Study population

23 Starting from 2006 and being followed up every two years, the Kailuan cohort is an ongoing 24 longitudinal prospective cohort based on the Kailuan community in Tangshan, China. In this 25 study, we enrolled 159,018 participants who entered the cohort between 2006-2013. We excluded 26 54,804 participants due to the following: (1) having liver cirrhosis at baseline (n=170); (2) 27 excessive alcohol consumption (alcohol intake \geq 30 g/day for men and \geq 20 g/day for women) or 28 with alcohol intake missing (n=42524); (3) hepatitis B surface antigen (HBsAg) positive or 29 missing (n=4931); (4) missing on the fatty liver by B ultrasound (n=6864); (5) death within one 30 year from the baseline (n=315); or (6) three or more missing values of MetS components (n=41). 31 Finally, 104,173 participants were included (Supplementary Figure 1).

The Ethics Committees of the Kailuan General Hospital and the Institute of Basic Medical
Sciences Chinese Academy of Medical Sciences approved this study. We obtained informed
consent from all participants.

35 2.2 Definition of NAFLD, MetS, and its metabolism components

Using abdominal ultrasonography (PHILIPS HD-15), fatty liver was diagnosed by experiencedradiologists blinded to clinical presentation and laboratory results. Participants with fatty liver

- 1 were defined as NAFLD because we excluded individuals with excessive alcohol consumption or
- 2 other causes of chronic liver disease. We utilized the diagnostic criteria proposed by the
- 3 International Diabetes Federation (2009) ¹⁶ to define MetS by the presence of \geq 3 of the following
- 4 components: abdominal obesity, elevated blood pressure (BP), fasting blood glucose (FBG) serum
- 5 triglyceride (TG), and high-density lipoprotein (HDL) (detailed in Supplementary text).

6 2.3 Follow-up and outcome assessment

7 We followed all the participants to the date of death, or 12-31-2019, which came first. Death 8 certificates were obtained annually from the Kailuan social security system and provincial vital 9 statistics offices. The cause of death listed on the death certificate was classified following the 10th version of the International Classification of Diseases (ICD-10). We defined the cause of death 10 11 due to cardiovascular disease (CVD) with codes of ICD-10 I00-I69¹⁷ and liver-related mortality with ICD-10 of C22, B15-B19, I85, K70- K76¹⁸. Death causes were collected before 31 12 December 2016, so the follow-up ended at the date of death or 12-31-2016 when analyzing the 13 14 risk of CVD-related and liver-related death.

15 2.4 Potential confounders

We conducted questionnaire surveys to collect demographic characteristics (age, sex, and education level), lifestyle factors (smoking, drinking, and physical activity), medical history, and medications of all the participants. Height, weight, waist, and blood pressure were measured by trained field workers. Laboratory tests, including TG, HDL, alanine aminotransferase (ALT), FBG, and HBsAg were assessed in the central lab.

21 2.5 Statistical methods

22 Variables were presented as mean \pm standard deviation or number (%) and compared using 23 analysis of variance or Chi-square test, respectively. The age- and sex- standardized prevalence of 24 MetS component for NAFLD and non-NAFLD populations were estimated using the Chinses 2010 census population as the reference ¹⁹. We conducted the Kaplan-Meier to calculate the 25 26 mortality rate. Compared to the non-NAFLD, the Cox proportional hazards model with age as the 27 timescale was used to estimate the HRs and 95% confidence intervals (CIs) of NAFLD with the 28 different numbers of MetS components after adjusting for age, sex, education, smoking, physical 29 activity, salt intake, and ALT level. We divided the participants into six groups (18-39, 40-49, 50-30 59, 60-69, 70-79, and \geq 80 years) because we found an age-dependent hazard ratio (HR) between 31 NAFLD and death risk (Supplementary Figure 2).We also conducted sensitivity analyses to verify 32 the results: (1) using the original complete dataset, (2) excluding females, (3) excluding drinkers, (4) defining NAFLD as the participants diagnosed with moderate or severe fatty liver for the low 33 sensitivity and specificity of ultrasound in the diagnosis of mild fatty liver ^{20,21}, and (5) excluding 34 participants with cancers or cardiovascular disease (myocardial infarction, stroke, subarachnoid 35 36 hemorrhage, cerebral infarction, cerebral hemorrhage or heart failure) at baseline.

- 1 Furthermore, we assessed the adjusted overall and age-specific population-attributable fraction
- 2 (PAF) of deaths that contributed to MetS components in the NAFLD and compared them with that
- 3 in the non-NAFLD using a method for cohort study 22 . We used multiple imputations by chained
- 4 equations to impute one complete dataset with five interactions, which showed equal distribution
- 5 before and after imputation (Supplementary Table 1).
- 6 Analyses were implemented with SAS version 9.4 (SAS Institute Inc. Cary, NC), R version 3.5.2
- 7 (https://www.r-project.org/), or Stata 15.0.

8 3. Results

9 3.1 Baseline characteristics and the prevalence of metabolic components

10 Among 104,173 participants with a mean age of 49.2±14.0 years old, NAFLD was identified in

11 32,384 (31.1%) participants, 74.9% of whom combined with >1 MetS component, significantly

12 higher than in the non-NAFLD (35.7%). In the NAFLD group, the average age and the proportion

13 of people with low education levels, high-intensity physical exercise, salt preference, and high

14 ALT gradually increased with the increasing number of MetS components (Table 1).

15 The standardized prevalence of each MetS component in the NAFLD group was significantly 16 higher than that in the non-NAFLD group (Table 2). The highest difference in prevalence between 17 NAFLD and non-NAFLD was abdominal obesity (62.7% vs. 27.3%), then the elevated TG (47.5%

18 *vs.* 18.4%) and elevated BP (50.9% *vs.* 30.7%).

3.2 Associations between NAFLD with the different numbers of MetS components and CVD-, liver-related, and all-cause mortality.

During a median follow-up of 12.7 years, 10442 subjects died. The 10-year all-cause mortality rates (Figure 1A) of the non-NAFLD (7.5%) were significantly lower than the NAFLD with 3 (10.3%) and 4-5 MetS components (11.6%) but higher than the NAFLD with 0-1 MetS component (1.5%), p < 0.001. Similar phenomena were observed in CVD-related death (Figure 1B, p < 0.001). Although existing an increased trend, we did not observe a significant difference in liver-related mortality between NAFLD with the different numbers of MetS components and non-NAFLD (Figure 1C, p=0.314).

28 3.3 Associations between NAFLD with the different numbers of MetS components and CVD-,

29 *liver-related, and all-cause mortality by age*

Figure 2A showed that the excess risk of all-cause mortality for NAFLD vs. non-NAFLD
increased with the number of metabolic component abnormalities but linearly declined with age.
In the subjects with 4-5 MetS components but aged < 40, NAFLD patients had the highest all-
cause mortality risk (HR=2.81, 95% CI:1.55-5.08, *p*=0.001).

34 For CVD-related mortality (Figure 2B), higher risks for NAFLD vs. non-NAFLD was only

- 1 observed in those aged 40-69 and with >2 MetS components. For the NAFLD patients with 3
- 2 MetS components, the HR(95% CI) for those aged 30-49, 50-59, and 60-69 was 2.25(1.46-3.45),
- 3 1.34(1.03-1.74), and 1.41(1.15-1.74). For NAFLD patients with 4-5 MetS components, the
- 4 HR(95% CI) at the corresponding age was 1.86 (0.97-3.57), 1.85(1.37-2.49), and 1.64(1.27-2.12).
- 5 However, we did not observe an excess risk of liver-related death risk in NAFLD patients in any
- 6 age group (figure 2C). So we did not perform further PAF-related analyses for liver-related death.
- 7 The sensitivity analysis showed a consistent result after excluding females, drinkers, individuals
- 8 with cancers or CVD, NAFLD with mild fatty liver, or using original data (Supplementary Table
- 9 2-4).

3.4 Association between metabolic components and all-cause and CVD-related death by NAFLD status

12 Table 3 showed the association between MetS components and all-cause mortality by NAFLD 13 status. Due to the limited outcome events in the NAFLD patients, we regrouped the age category 14 into <50, 50-69, and \geq 70 years. Both in the NAFLD and non-NAFLD populations, elevated FBG 15 (HR=1.36, 95% CI:1.27-1.46 in the NAFLD; HR=1.29, 95% CI:1.23-1.36 in the non-NAFLD) 16 and elevated BP (HR=1.49, 95% CI:1.38-1.62 in the NAFLD; HR=1.39, 95% CI:1.32-1.47 in the 17 non-NAFLD) were significantly associated with all-cause death after multivariable adjustments. 18 Elevated TG (HR=1.08, 95% CI:1.01-1.16) was only observed to be a risk factor for death in the 19 NAFLD, and abdominal obesity in the non-NAFLD (HR=1.07, 95% CI:1.01-1.12). However, 20 HRs of elevated BP on death declined with age in both NAFLD and non-NAFLD groups. 21 HR(95%CI) decreased from 1.66(1.32-2.09) for those aged 18-49 to 1.21(1.04-1.40) for those 22 aged ≥ 70 in the NAFLD and from 1.66 (1.40-1.98) to 1.12(1.03-1.21) in the non-NAFLD 23 correspondingly.

Regarding CVD-related death (Table 4), the results were similar to all-cause mortality. The risk
effect of elevated BP (HR=1.94, 95% CI:1.63-2.30 in the NAFLD; HR=1.65, 95% CI:1.49-1.84 in
the non-NAFLD) and evaluated TG ((HR=1.33, 95% CI:1.16-153 in the NAFLD; HR=1.13, 95%
CI:1.01-1.27 in the non-NAFLD) on CVD-related death was more prominent than that on the allcause mortality. And the risk effect of evaluated TG also declined with age. HR(95%CI) decreased
from 1.58(0.99-2.55) to 1.24(0.98-1.57) in the NAFLD group and from 1.56(1.02-2.37) to
1.03(0.85-1.24) in the non-NAFLD group.

3.5 PAFs of metabolic components to all-cause/CVD-related mortality among NAFLD and non-NAFLD patients

- The prevalence of MetS components by age was shown in Supplementary Table 5. The MetS
 components increased with age, except for the reduced HDL in the NAFLD and non-NAFLD
 participants.
- Table 3 showed the PAFs of MetS components to all-cause death by NAFLD status. For bothNAFLD and non-NAFLD participants, the largest adjusted PAF of MetS components was elevated

- 1 BP (24.7% in the NAFLD and 17.0% in the non-NAFLD), and then the elevated FBG (13.4% in
- 2 the NAFLD and 7.5% in the non-NAFLD). With age increasing, the PAF of elevated BP (from
- 3 26.2% to 13.0% in the NAFLD and from 17.6% to 6.8% in the non-NAFLD) and elevated FBG
- 4 (from 12.7% to 8.5% in the NAFLD, and from 11.8% to 2.7% in the non-NAFLD) were both
- 5 declined.
- 6 Like all-cause of death, elevated BP had the largest adjusted PAF for CVD-related death in both
- 7 NAFLD patients (38.6%) and non-NAFLD (25.9%) (Table 4). However, the elevated TG (14.0%)
- 8 had a slightly higher PAF than the elevated FBG (9.2%) for NAFLD patients. The elevated FBG
- 9 (8.5%) still had the second-largest PAF for non-NAFLD patients. Similarly, the PAFs of elevated
- 10 BP (from 44.9% to 20.9% in the NAFLD and from 19.9% to 8.0% in the non-NAFLD) and
- 11 elevated TG (from 24.0% to 9.7% in the NAFLD, and from 11.7% to 0.5% in the non-NAFLD)
- 12 dramatically declined with age.
- 13 For the multiple MetS components, 28.5% of all-cause deaths and 43.4% of CVD-related deaths
- 14 could be potentially averted by controlling the subjects with NAFLD to combining less than one
- 15 MetS component, more than twice in the subjects without NAFLD (all-cause mortality: 12.5%;
- 16 CVD-related mortality: 16.3%).

17 4. Discussion

18 Our study found that the standardized prevalence of abdominal obesity, elevated BP, TG, and 19 FBG, and reduced HDL reached 62.7%, 50.9%, 47.5%, 36.9%, and 21.8% among NAFLD 20 patients, respectively. Compared to non-NAFLD, The highest all-cause and CVD-related death 21 risks were observed in NAFLD aged 18-39 with 4-5 MetS (HR=2.81, 95% CI:1.55-5.08) and 22 those aged 40-49 years with 3 MetS (HR=2.25, 95% CI:1.55-5.08). Higher than in non-NAFLD, 23 all-cause of death could be attributable to 24.7% of elevated BP and 13.4% of elevated FBG in the 24 NAFLD population. Similarly, CVD-related death could be attributable to 38.6% of high BP, 25 9.2% of elevated FBG, and 14.0% of elevated TG.

Our analysis showed that patients with NAFLD aged 18-39 with 4-5 MetS components had the highest excess risk of all-cause mortality compared with non-NAFLD. Notably, we identified a monotonic relationship between the increasing age of NAFLD patients and lowered extra risk of all-cause mortality and CVD-related mortality, which could be supported by the research on the early onset of hypertension ¹², obesity ¹³, and diabetes ¹⁴ to the excess deaths or CVD-related mortality.

The present study indicated that 28.5% of all-cause deaths and 43.4% of CVD-related deaths among NAFLD patients could be attributable to presenting ≥2 MetS component, suggesting that reducing MetS components <1 may substantially reduce mortality, consistent with a previous study using the NHANES III data ²³. Furthermore, our study showed that 24.7% of the all-cause and 38.6% of CVD-related mortality in NAFLD participants were attributable to elevated BP, slightly lower than a study from the NHANES III data (adjusted PAF of 23% of all-cause and 52.8% of CVD-related mortality) ²³. With a prevalence of elevated BP of 50.9% in our NAFLD

population, hypertension is an independent driver of the progression of NAFLD to non-alcoholic
steatohepatitis, advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma ^{24,25}. Also, CVD
risk has been proven to be increased with more advanced liver disease from a meta-analysis of 36

4 longitudinal studies, furtherly supporting our results². Our former study found that even in the

5 NAFLD with normal BMI, those with hypertension had a higher risk of all-cause death and CVD

 2^{-26}

6 ²⁶, suggesting the importance of controlling blood pressure for NAFLD participants.

7 Elevated FBG was found to be attributed to 13.4% of all-cause mortality in NAFLD, higher than 8 that in non-NAFLD (7.5%). The higher prevalence of elevated FBG in the NAFLD (36.9%) than 9 that in non-NAFLD (20.0%) could explain the difference since the similar HR for elevated FBG 10 and all-cause mortality in the NAFLD (HR=1.36) and non-NAFLD (HR=1.29) group. Similar 11 results were observed for CVD-related death (PAF: 13.4% in NAFLD vs. 7.5% in non-NAFLD). Diabetes could promote NAFLD progression to cirrhosis and fibrosis and increase the all-cause 12 mortality risk^{27,28}. Insulin resistance could explain the higher risk of all-cause and CVD-related 13 14 mortality in the participants with elevated FBG.

15 Elevated TG was found to be the second-largest contributor to CVD-related death (PAF=14%) in 16 NAFLD patients, higher than that of elevated FBG (9.2%). It can be explained by the significant 17 risk effect (elevated TG: HR=1.33 vs. elevated FBG: HR=1.23) and higher prevalence (elevated 18 TG: 47.5% vs. elevated FBG: 36.9%) of elevated TG in NAFLD patients. Serum elevated TG has 19 been suggested to be an indicator of atherogenic dyslipidemia. Together with hyperglycemia, oxidative stress and inflammation activation, dysregulated lipid metabolism could create a pro-20 atherogenic environment attributing to CVD development ²⁹. We also found that the PAFs of 21 22 elevated BP and elevated TG to all-cause or CVD-related mortality in NAFLD patients declined 23 with age, which could be explained by the decreased HRs of elevated BP and TG with age.

This study has some limitations. Firstly, we did not collect hepatitis C infection information, so patients with hepatitis C were not excluded. However, given the relatively low rate of hepatitis C infection in the Chinese population (1%-3%), the estimated association between NAFLD, MetS, and all-cause mortality has little impact ³⁰. Secondly, 80% of the participants were male, so the impact of NAFLD and MetS components on all-cause mortality in females and its potential sex differences needs further exploration. Finally, the association between NAFLD and liver-related mortality needs more cases and longer follow-ups to prove.

31 5. Conclusion

For NAFLD patients combined with more than one MetS component, its excess risk of all-cause
 and CVD-related mortality decreased with age. Substantial proportions of deaths, especially CVD related deaths, could be averted if NAFLD patients are controlled under two MetS components,

35 especially controlling elevated blood pressure, fasting glucose, and triglycerides.

36 Acknowledgement

- 1 The authors thank all the members of the Kailuan Study Team for their contribution and the
- 2 participants who contributed their data.
- 3 Funding: This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS)(2021-
- 4 I2M-1-023), the Capital's Funds for Health Improvement and Research (CHF 2022-1-2021), and the
- 5 Beijing Municipal Administration of Hospitals Incubating Program (PX2022001).

6 Declarations

- 7 Conflict of interest: All authors, including Xinyu Zhao, Shuohua Chen, Xiao mo Wang, Zhenyu
- 8 Wang , Yuanyuan Sun , Chenlu Yang , Mengyi Zheng , Yanhong Wang, Wei Liao, Shouling Wu, and
- 9 Li Wang, report no conflicts of interest.

Ethical approval and Informed consent: The Ethics Committees of the Kailuan General Hospital
 and the Institute of Basic Medical Sciences Chinese Academy of Medical Sciences approved this
 study. We obtained informed consent from all participants.

13 Data availability: The data used or analyzed during this study are included in this article and available
14 from the corresponding author upon reasonable request.

15

16 Reference

17	1	Youngssi 7M, Golahi P, Baik IM, Hanny A, Van Dongon C, Honny L, The global epidemiology of
17	1.	Touriossi zivi, Golabi P, Paik Jivi, Henry A, Van Dongen C, Henry L. The global epidemiology of
18		nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a
19		systematic review. Hepatology. 2023;77:1335-1347. doi: 10.1097/hep.0000000000000004
20	2.	Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G.
21		Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an
22		updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903-913.
23		doi: 10.1016/S2468-1253(21)00308-3
24	3.	Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship
25		with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153. doi:
26		10.1136/gutjnl-2017-313884
27	4.	Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical
28		outcomes in chronic kidney disease. Nephrol Dial Transplant. 2019;34:449-457. doi:
29		10.1093/ndt/gfx381
30	5.	Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, Calabria S, Scaturro G,
31		Mantovani A, Zoppini G, et al. Non-alcoholic fatty liver disease and increased risk of all-cause
32		mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018;265:162-168.
33		doi: 10.1016/j.ijcard.2018.04.129
34	6.	Hwang Y-C, Ahn H-Y, Park S-W, Park C-Y. Nonalcoholic Fatty Liver Disease Associates With
35		Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver

1 2		Disease in Women but Not Men. <i>Clinical gastroenterology and hepatology</i> . 2018;16:1131-
2 3	7	Carrillo-Larco BM Guzman-Vilca WC Castillo-Cara M Alvizuri-Gomez C Algabtani S Garcia-
4	7.	Larsen V. Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality:
5		unsupervised machine learning analysis of NHANES III <i>BMI Open</i> 2022:12:e067203 doi:
6		10.1136/hmionen-2022-067203
7	0	van Kloof LA Sonnovold ML Kavousi M Ikram MA de Man PA de Knogt PL Eatty liver disease
י 8	0.	is not associated with increased mertality in the elderly. A prospective sobert study
0		Hangtology 2022:77:585 502 doi: 10.1002/bop.22625
9 10	٥	Wild SH Walker II. Merling IP. McAllister DA. Colbour HM. Earran R. McGurnaghan S.
11	5.	McCrimmon R. Read SH. Sattar N. et al. Cardiovascular Disease. Cancer and Mortality Among
12		People With Type 2 Diabetes and Alcoholic or Nonalcoholic Eatty Liver Disease Hosnital
13		Admission Diabetes Care 2018:41:341-347 doi: 10.2337/dc17-1590
1/	10	Kockin M. Haveroğlu Mİ. Have AO. Güvene TS. Sahin S. Kozan Ö. Effect of Nonalcoholic Fatty
15	10.	Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation
16		Myocardial Infarction Am / Cardial 2017;120:1720-1726 doi:
17		10 1016/i amicard 2017 07 107
18	11	Pegah Golahi Munkhzul Otgonsuren Levla Avila d Mehmet Saviner Nila Rafig
19	11.	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver
20		disease (NAFLD) Medicine 2018:e0214
21	12	Wang C Yuan Y Zheng M Pan A Wang M Zhao M Li Y Yao S Chen S Wu S et al. Association
22		of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality. <i>J Am Coll</i>
23		<i>Cardiol.</i> 2020:75:2921-2930. doi: 10.1016/i.jacc.2020.04.038
24	13.	Wang Z. Age-dependent decline of association between obesity and mortality: a systematic
25		review and meta-analysis. <i>Obesity research & clinical practice</i> , 2015:9:1-11. doi:
26		10.1016/j.orcp.2014.01.006
27	14.	Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A, McGuire DK,
28		Eliasson B, Gudbjörnsdottir S. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations
29		With Cardiovascular and Mortality Risks. <i>Circulation</i> . 2019;139:2228-2237. doi:
30		10.1161/circulationaha.118.037885
31	15.	Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, Lan Y, Hu S, Wang Y, Lu Y, et al. Metabolic
32		Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a
33		Prospective Cohort Study. J Clin Endocrinol Metab. 2022;107:e745-e755. doi:
34		10.1210/clinem/dgab644
35	16.	Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, James
36		WPT, Loria CM, Smith SC. Harmonizing the Metabolic Syndrome. <i>Circulation</i> . 2009;120:1640-
37		1645. doi: doi:10.1161/CIRCULATIONAHA.109.192644
38	17.	Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic
39		fatty liver disease and mortality among US adults: prospective cohort study. Bmj.
40		2011;343:d6891. doi: 10.1136/bmj.d6891
41	18.	Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related
42		mortality in the United States. <i>Gastroenterology</i> . 2013;145:375-382.e371-372. doi:
43		10.1053/j.gastro.2013.04.005
44	19.	Census Office of The State Council PaESDotNBoS. Tabulation on the population census of the

1		people's republic of China by county 2010. China Statistics Press; 2012.
2	20.	Hernaez R, Lazo M, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Diagnostic
3		accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis.
4		Hepatology. 2011;54:1082-1090.
5	21.	Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-
6		alcoholic steatohepatitis. Clinics in Liver Disease. 2007;11:37-54.
7	22.	Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population
8		attributable risks in cohort studies: examples and software. Cancer Causes Control.
9		2007;18:571-579. doi: 10.1007/s10552-006-0090-y
10	23.	Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable
11		risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Alimentary
12		pharmacology & therapeutics. 2020;51:291-304. doi: 10.1111/apt.15580
13	24.	Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, Asch SM, El-Serag HB. Effect of Metabolic
14		Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
15		Hepatology. 2020;71:808-819. doi: 10.1002/hep.31014
16	25.	Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic Fatty Liver Disease
17		and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension.
18		2020;76:562-568. doi: 10.1161/HYPERTENSIONAHA.120.15220
19	26.	Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y, Yuan X, Liu H, Wang X, Wu S, et al. Outcomes of subjects
20		who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in
21		China. Hepatol Commun. 2022;6:3393-3405. doi: 10.1002/hep4.2081
22	27.	Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, Piercy DL, Seymour KA,
23		Sudan R, Portenier DD, et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and
24		Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021;74:1220-1233. doi:
25		10.1002/hep.31806
26	28.	Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver
27		diseases in diabetes. Am J Gastroenterol. 2014;109:1020-1025. doi: 10.1038/ajg.2014.132
28	29.	Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular
29		disease. Mol Metab. 2020;42:101092. doi: 10.1016/j.molmet.2020.101092
30	30.	de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution
31		of hepatitis B and C viruses in hepatocellular carcinoma. <i>Hepatology</i> . 2015;62:1190-1200.
32		doi: 10.1002/hep.27969
33		
34	Figure	legends:
35		
36	Figure	1. The cumulative all-cause, CVD-, and liver-related mortality rates of participants
37	with dif	fferent numbers of metabolic syndrome components
38		
39	Figure	2. The excess risk of all-cause, CVD-, and liver-related mortality among patients with
40	NAFLI	<i>) vs.</i> non-NAFLD according to the number of metabolic components.
41	Adjuste	d HRs: Adjusted for sex, education, smoking, physical activity, salt intake, and alanine
42	aminotr	ansferase.
43		

Table1. Baseline characteristics of subjects with and without NAFLD.

	Non-		NAFLD			р-
Variable	NAFLD	G ₀₋₁	G ₂	G ₃	G ₄₋₅	value
N	71789	8115	10229	9260	4780	
Age, years	49.1±14.6	48.5±12.9	51.6±12.7	53.4±12.1	54.3±11.5	< 0.001
Male	52865(73.6)	6403(78.9)	8172(79.9)	7211(77.9)	3485(72.9)	< 0.001
Education						< 0.001
Primary school or below	6355(8.9)	541(6.7)	897(8.8)	958(10.3)	555(11.6)	
Junior high school	47265(65.8)	5437(67.0)	7129(69.7)	6509(70.3)	3341(69.9)	
Senior high school	10750(15.0)	1243(15.3)	1412(13.8)	1214(13.1)	589(12.3)	
College and above	7419(10.3)	894(11.0)	791(7.7)	579(6.3)	295(6.2)	
Physical activity level*						0.003
Inactive	8765(12.2)	1002(12.3)	1202(11.8)	1044(11.3)	534(11.2)	
Moderate	53227(74.1)	6127(75.5)	7623(74.5)	6843(73.9)	3397(71.1)	
Frequently	9797(13.6)	986(12.2)	1404(13.7)	1373(14.8)	849(17.8)	
Smoking status						< 0.001
Never	52061(72.5)	5692(70.1)	7150(69.9)	6484(70.0)	3367(70.4)	
Past	2923(4.1)	341(4.2)	584(5.7)	552(6.0)	270(5.6)	
Current	16805(23.4)	2082(25.7)	2495(24.4)	2224(24.0)	1143(23.9)	
Salt intake						< 0.001
Low (<6g/d)	7391(10.3)	790(9.7)	982(9.6)	905(9.8)	484(10.1)	
Medium (6-11g/d)	58454(81.4)	6627(81.7)	8200(80.2)	7429(80.2)	3731(78.1)	
High (>11g/d)	5944(8.3)	698(8.6)	1047(10.2)	926(10.0)	565(11.8)	
ALT (U/L)						< 0.001
<40	69126(96.3)	7279(89.7)	8917(87.2)	7898(85.3)	3943(82.5)	
40-79	2246(3.1)	713(8.8)	1099(10.7)	1138(12.3)	697(14.6)	
80-	417(0.6)	123(1.5)	213(2.1)	224(2.4)	140(2.9)	

Data are presented as mean (standard deviation) or number (percentage).

*We defined physical activity as inactive, moderately active, and active regarding the frequency of physical activity (≥ 20 min/time) during leisure time with responses of never, sometimes, and \geq four times/week, respectively.

Abbreviations: NAFLD: Non-alcoholic fatty liver disease; G₀₋₁, G₂, G₃, G₄₋₅: with 0-1, 2, 3, and 4-5 metabolic syndrome components, respectively; ALT, aminotransferase.

	nor	n-NAFLD	NA		
MetS components	n/N	Standardized prevalence (%)	n/N	Standardized prevalence (%)	P
Total population					
Elevated FBG	16935/71789	20.0	13166/32384	36.9	< 0.001
Elevated BP	27109/71789	30.7	19147/32384	50.9	< 0.001
Abdominal Obesity	21063/71789	27.3	20889/32384	62.7	< 0.001
Elevated TG	14245/71789	18.4	16184/32384	47.5	< 0.001
Reduced HDL	7821/71789	15.1	4738/32384	21.8	< 0.001
G ₀₋₁	46167/71789	68.2	8129/32384	29.0	< 0.001
G ₂	16746/71789	21.0	10197/32384	30.5	< 0.001
G ₃	7054/71789	8.5	9285/32384	26.5	< 0.001
G ₄₋₅	1822/71789	2.3	4773/32384	14.0	< 0.001

Table 2. Standardized prevalence of metabolic syndrome components stratified by NAFLD.

Standardized prevalence: based on the direct standardization method using the Chinses 2010 census population as the reference; Elevated FBG: administration of anti-diabetes drugs or fasting blood glucose \geq 5.6 mmol/L; elevated BP: administration of anti-hypertensive drugs and(or) systolic blood pressure(SBP) \geq 140 mmHg or diastolic blood pressure(DBP) \geq 90 mmHg; abdominal obesity: waist circumference > 90 cm(male) or > 85 cm(female); elevated TG: TG \geq 1.7 mmol/L; reduced HDL: HDL < 1.0 mmol/L(male) or < 1.3 mmol/L(female). Abbreviations: NAFLD: Non-alcoholic fatty liver disease; MetS: metabolic syndrome; FBG: fasting blood glucose; BP: blood pressure; TG: triglycerides; HDL: high-density lipoprotein cholesterol; G₀₋₁, G₂, G₃, G₄₋₅: with 0-1, 2, 3, and 4-5 metabolic syndrome components, respectively.

		NAFLD	non-	-NAFLD
MetS components	HR (95%CI)	PAF (95%CI)	HR (95%CI)	PAF (95%CI)
Elevated FBG				
All age groups	1.36(1.27-1.46)	13.4(10.2-16.6)	1.29(1.23-1.36)	7.5(5.8-9.2)
18-49 years old	1.39(1.12-1.72)	12.7(3.6-21.5)	1.61(1.34-1.94)	11.8(6.4-17.2)
50-69 years old	1.43(1.30-1.56)	16.0(11.7-20.2)	1.39(1.29-1.49)	10.3(7.7-0.12.9)
70 years old or older	1.22(1.07-1.38)	8.5(2.8-14.1)	1.10(1.01-1.20)	2.7(0.2-5.1)
Elevated BP				
All age groups	1.49(1.38-1.62)	24.7(20.1-29.3)	1.39(1.32-1.47)	17.0(14.3-19.7)
18-49 years old	1.66(1.32-2.09)	26.2(14.7-37.1)	1.66(1.40-1.98)	17.6(10.7-24.4)
50-69 years old	1.60(1.44-1.77)	28.3(22.4-34.0)	1.56(1.45-1.68)	21.7(18.2-25.2)
70 years old or older	1.21(1.04-1.40)	13.0(3.3-22.6)	1.12(1.03-1.21)	6.8(2.0-11.5)
Abdominal obesity				
All age groups	1.07(0.99-1.16)	5.0(0.0-10.3)	1.07(1.01-1.12)	2.4(0.4-4.4)
18-49 years old	1.00(0.80-1.24)	-	1.26(1.05-1.51)	6.5(0.8-12.1)
50-69 years old	1.17(1.05-1.29)	10.3(3.6-16.9)	1.11(1.03-1.19)	3.8(1.0-6.6)
70 years old or older	0.93(0.80-1.08)	-	0.97(0.90-1.05)	-
Reduced HDL				
All age groups	0.80(0.71-0.89)	-	0.89(0.81-0.98)	-
18-49 years old	1.04(0.75-1.45)	0.5(0.0-4.5)	0.61(0.44-0.85)	-
50-69 years old	0.70(0.60-0.82)	-	0.91(0.80-1.05)	-
70 years old or older	0.93(0.75-1.14)	-	1.02(0.87-1.20)	0.2(0.0-1.2)
Elevated TG				
All age groups	1.08(1.01-1.16)	3.9(0.4-7.3)	1.05(0.99-1.12)	1.1(0.0-2.4)
18-49 years old	1.09(0.87-1.35)	4.5(7.5-16.4)	1.25(1.03-1.51)	5.3(0.0-10.7)
50-69 years old	1.06(0.97-1.16)	3.1(0.0-7.8)	1.07(0.99-1.16)	1.7(0.0-3.8)
70 years old or older	1.11(0.98-1.26)	4.6(0.0-10.3)	0.94(0.85-1.04)	-
≥2 MetS components				
All age groups	1.51(1.37-1.66)	28.5(22.5-34.2)	1.32(1.26-1.39)	12.5(10.2-14.7)
18-49 years old	1.38(1.08-1.78)	21.2(5.5-35.8)	1.75(1.48-2.07)	18.4(12.3-24.5)
50-69 years old	1.60(1.41-1.82)	32.3(24.5-39.6)	1.51(1.41-1.62)	18.3(15.1-21.4)
70 years old or older	1.35(1.13-1.61)	22.0(10.0-33.5)	1.04(0.96-1.12)	1.7(2.1-5.5)

Table 3. Adjusted hazard ratios and population-attributable fractions (95% CI) of metabolic components to all-cause mortality by NAFLD status

Elevated FBG: administration of anti-diabetes drugs or fasting blood glucose \geq 5.6 mmol/L; elevated BP: a dministration of anti-hypertensive drugs or systolic blood pressure(SBP) \geq 140 mmHg or diastolic blood pressure(DBP) \geq 90 mmHg; abdominal obesity: waist circumference > 90

cm(male) or > 85 cm(female); elevated TG: TG \ge 1.7 mmol/L; reduced HDL: HDL < 1.0 mmol/L(male) or < 1.3 mmol/L(female).

Abbreviations: NAFLD: Non-alcoholic fatty liver disease; MetS: metabolic syndrome; FBG: fasting blood glucose; BP: blood pressure; TG: triglycerides; HDL: high-density lipoprotein cholesterol; G_{0-1} , G_2 , G_3 , G_{4-5} : with 0-1, 2, 3, and 4-5 metabolic syndrome components, respectively.

Note: The individual PAF cannot be computed for health metrics with adjusted HRs < 1.0. The negative values of the lower 95% CI in PAF were rounded to zero. HRs of each metabolism syndrome were estimated after adjusting age, sex, education, smoke status, physical activity, salt intake, ALT level, and the other 4 MetS components. HRs of the MetS components were calculated after adjusting age, sex, education, smoke status, physical activity, salt intake, and aminotransferase level. In the subgroup analyses by age, age was not adjusted.

Table 4. Adjusted hazard ratios and population-attributable fractions (95% CI) of metabolic components to CVD-related

mortality by NAFLD status.								
NAFLD non-NAFLD								
MetS components	HR (95%CI)	HR (95%CI) PAF (95%CI)		PAF (95%CI)				
Elevated FBG								
All age groups	1.23(1.07-1.41)	9.2(3.0-15.4)	1.33(1.20-1.48)	8.5(5.1-12.0)				
18-49 years old	1.18(0.75-1.85)	6.4(0.0-24.5)	2.04(1.36-3.05)	18.9(5.2-32.0)				
50-69 years old	1.30(1.09-1.56)	12.2(3.7-20.5)	1.51(1.31-1.76)	13.6(8.1-19.0)				
70 years old or older	1.08(0.85-1.37)	3.4(0.0-14.0)	1.05(0.89-1.23)	1.3(0.0-5.8)				
Elevated BP								
All age groups	1.94(1.63-2.30)	38.6(29.9-46.8)	1.65(1.49-1.84)	25.9(20.5-31.1)				
18-49 years old	2.48(1.46-4.19)	44.9(20.4-64.1)	1.73(1.17-2.57)	19.9(3.3-35.5)				
50-69 years old	2.21(1.76-2.78)	44.6(33.5-54.4)	2.25(1.92-2.63)	38.4(31.2-45.1)				
70 years old or older	1.37(1.03-1.82)	20.9(2.7-37.9)	1.14(0.98-1.33)	8.0(0.0-17.0)				
Abdominal obesity								
All age groups	1.09(0.93-1.27)	6.0(0.0-16.7)	1.08(0.98-1.20)	3.0(0.0-7.1)				
18-49 years old	0.90(0.57-1.43)	-	1.44(0.96-2.17)	11.0(0.0-24.5)				
50-69 years old	1.18(0.97-1.45)	11.2(0.0-24.3)	1.11(0.96-1.29)	4.2(0.0-10.1)				
70 years old or older	1.00(0.75-1.33)	-	0.99(0.86-1.15)	-				
Reduced HDL								
All age groups	0.76(0.60-0.97)	-	0.80(0.65-0.99)	-				
18-49 years old	0.71(0.31-1.64)	-	0.52(0.23-1.19)	-				
50-69 years old	0.71(0.52-0.96)	-	0.76(0.56-1.03)	-				
70 years old or older	0.88(0.59-1.33)	-	0.98(0.72-1.32)	-				
Elevated TG								
All age groups	1.33(1.16-1.53)	14.0(7.1-20.8)	1.13(1.01-1.27)	2.7(0.0-5.5)				
18-49 years old	1.58(0.99-2.55)	24.0(0.0-47.4)	1.56(1.02-2.37)	11.7(0.0-25.6)				
50-69 years old	1.34(1.12-1.61)	15.0(5.6-24.3)	1.14(0.96-1.34)	3.2(0.0-7.6)				
70 years old or older	1.24(0.98-1.57)	9.7(0.0-20.4)	1.03(0.85-1.24)	0.5(0.0-4.0)				
≥2 MetS components								
All age groups	1.97(1.60-2.43)	43.4(32.3-53.3)	1.43(1.29-1.58)	16.3(11.7-20.8)				
18-49 years old	2.36(1.27-4.38)	48.7(17.2-71.2)	2.30(1.57-3.39)	28.3(13.6-41.8)				
50-69 years old	2.16(1.62-2.87)	47.9(33.5-60.1)	1.78(1.54-2.06)	25.6(19.1-31.8)				
70 years old or older	1.51(1.06-2.15)	29.4(0.0-49.5)	1.05(0.91-1.21)	2.3(0.0-9.4)				

Elevated FBG: administration of anti-diabetes drugs or fasting blood glucose \geq 5.6 mmol/L; elevated BP: administration of anti-hypertensive drugs and(or) systolic blood pressure(SBP) \geq 140 mmHg or diastolic blood pressure(DBP) \geq 90 mmHg; abdominal obesity: waist circumference >

90 cm(male) or > 85 cm(female); elevated TG: TG \geq 1.7 mmol/L; reduced HDL: HDL < 1.0 mmol/L(male) or < 1.3 mmol/L(female).

Abbreviations: CVD: cerebrovascular disease; NAFLD: Non-alcoholic fatty liver disease; MetS: metabolic syndrome; FBG: fasting blood glucose; BP: blood pressure; TG: triglycerides; HDL: high-density lipoprotein cholesterol; G_{0-1} , G_2 , G_3 , G_{4-5} : with 0-1, 2, 3, and 4-5 metabolic syndrome components, respectively.

Note: The individual PAF cannot be computed for health metrics with adjusted HRs <1.0. The negative values of the lower 95% CI in PAF were rounded to zero. HRs of each metabolism syndrome were estimated after adjusting for age, sex, education, smoke status, physical activity, salt intake, ALT level, and the other 4 MetS components. HRs of MetS components were calculated after adjusting age, sex, education, smoke status, physical activity, salt intake, and aminotransferase level. In the subgroup analyses by age, age was not adjusted.



А

С

CVD-related mortality

Liver-related mortality

Groups	Death/N	Adjusted HR(95%CI)		p value	Death/N	Adjusted HR(95%	6CI)	p value	Death/N	Adjusted HR(95%C	I)	p value
non-NAFLD 18-39 years old 40-49 years old 50-59 years old 60-69 years old 70-79 years old 80 years old or older	115/18984 502/16990 1486/20426 1967/9489 2097/4667 715/1233	reference reference reference reference reference reference	•		13/18984 92/16990 290/20426 457/9489 533/4667 206/1233	reference reference reference reference reference reference	* * *		6/18984 16/16990 43/20426 27/9489 22/4667 4/1233	reference) reference 2 reference reference reference reference	*	
18-39 years old 40-49 years old 50-59 years old 60-69 years old 70-79 years old 80 years old or older	17/1967 72/2207 176/2627 130/894 115/330 44/90	$\begin{array}{c} 1.20(0.72-2.01)\\ 1.06(0.82-1.35)\\ 0.99(0.84-1.15)\\ 0.79(0.66-0.94)\\ 0.79(0.66-0.96)\\ 0.85(0.63-1.16) \end{array}$		0.488 0.665 0.857 0.008 0.016 0.301	2/1967 10/2207 30/2627 23/894 25/330 10/90	$\begin{array}{c} 1.33(0.30{-}5.88)\\ 0.84(0.44{-}1.62)\\ 0.84(0.58{-}1.22)\\ 0.61(0.40{-}0.93)\\ 0.69(0.46{-}1.03)\\ 0.68(0.36{-}1.28) \end{array}$		0.711 0.610 0.359 0.022 0.070 0.227	1/1967 3/2207 4/2627 0/894 1/330 0/90	1.21(0.14-10.21) 1.31(0.38-4.51) 0.80(0.29-2.22) - 0.68(0.09-5.02) -		0.858 0.667 0.665 0.702
18-39 years old 40-49 years old 50-59 years old 60-69 years old 70-79 years old 80 years old or older	20/1723 92/2434 279/3732 328/1594 272/614 73/132	1.47(0.90-2.39) 1.14(0.91-1.42) 1.07(0.94-1.21) 1.10(0.98-1.24) 1.04(0.92-1.18) 0.98(0.77-1.25)		0.121 0.264 0.326 0.111 0.511 0.87	4/1723 21/2434 51/3732 86/1594 72/614 23/132	2.89(0.94-8.87) 1.56(0.97-2.50) 0.97(0.72-1.31) 1.20(0.95-1.51) 1.04(0.81-1.33) 1.07(0.69-1.64)		0.063 0.067 0.858 0.124 0.756 0.763	1/1723 2/2434 3/3732 3/1594 4/614 0/132	1.28(0.15-10.81) 0.74(0.17-3.20) 0.40(0.12-1.29) 0.70(0.21-2.31) 1.40(0.48-4.08)		0.820 0.682 0.124 0.558 0.533
18-39 years old 40-49 years old 50-59 years old 60-69 years old 70-79 years old 80 years old or older	13/1142 100/2135 319/3508 443/1729 286/612 84/134	1.33(0.74-2.40) 1.37(1.10-1.70) 1.30(1.15-1.46) 1.38(1.25-1.53) 1.14(1.01-1.29) 1.22(0.97-1.53)	1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	0.334 0.005 <0.001 <0.001 0.039 0.087	3/1142 27/2135 68/3508 114/1729 73/612 21/134	2.95(0.84-10.35) 2.25(1.46-3.45) 1.34(1.03-1.74) 1.41(1.15-1.74) 1.05(0.82-1.34) 0.95(0.61-1.49)		0.092 <0.001 0.032 0.001 0.689 0.820	0/1142 2/2135 3/3508 6/1729 0/612 0/134	- 0.82(0.19-3.56) 0.42(0.13-1.36) 1.29(0.53-3.14) -		0.787 0.149 0.569
18-39 years old 40-49 years old 50-59 years old 60-69 years old 70-79 years old 80 years old or older	3/500 53/1001 189/1921 243/947 169/354 30/57	2.81(1.55-5.08) 1.64(1.23-2.18) 1.47(1.26-1.71) 1.53(1.34-1.75) 1.21(1.04-1.42) 1.01(0.70-1.46)		0.001 0.001 <0.001 <0.001 0.016 0.952 3 5	1/500 10/1001 51/1921 68/947 48/354 11/57	1.96(0.26-15.02) 1.86(0.97-3.57) 1.85(1.37-2.49) 1.64(1.27-2.12) 1.22(0.91-1.64) 1.33(0.72-2.43)		0.516 0.062 <0.001 <0.001 0.185 0.362	0/500 2/1001 4/1921 3/947 2/354 0/57	- 1.97(0.45-8.57) 1.08(0.39-3.01) 1.27(0.38-4.22) 1.24(0.29-5.33) -		0.366 0.884 0.693 0.769

В

All-cause mortality